Latest news with #AdOral
Business Wire
22-05-2025
- Business
- Business Wire
ADOCIA Confirms its Eligibility for the PEA‑PME Scheme
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no withdrawals are made during the first 5 years. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext ™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the 'Risk Factors' section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
Business Wire
21-05-2025
- Business
- Business Wire
ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 11 th, 2025 in Paris
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders' meeting ('AGM') on June 11 th, 2025, at 2:00 pm, in the Jones Day's offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris. The notice of this shareholders' meeting, which serves as the convening notice was published on May 7 th, 2025, in the French Bulletin des Annonces Légales Obligatoires ('BALO'). It includes the agenda, the proposed resolutions and instructions for participating and voting at this meeting. In accordance with the regulations in force, all documentation concerning the meeting is available to shareholders on the company's website: Precisions regarding the AGM Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight (Paris time), will be able to participate physically in the AGM. Shareholders holding bearer shares (' actions au porteur ') will need to obtain a certificate of shareholding (' attestation de participation ') from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The ' attestation de participation ' may replace the admission card for shareholders wishing to attend the AGM in person. Shareholders must submit written questions no later than the fourth business day prior to the AGM. Questions can be sent by registered mail to the company's registered office or by email to the following address: ag2025@ In order to be considered, questions must be accompanied by an ' attestation de participation'. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext ™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the 'Risk Factors' section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
Yahoo
21-05-2025
- Business
- Yahoo
ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 11th, 2025 in Paris
LYON, France, May 21, 2025--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders' meeting ("AGM") on June 11th, 2025, at 2:00 pm, in the Jones Day's offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris. The notice of this shareholders' meeting, which serves as the convening notice was published on May 7th, 2025, in the French Bulletin des Annonces Légales Obligatoires ("BALO"). It includes the agenda, the proposed resolutions and instructions for participating and voting at this meeting. In accordance with the regulations in force, all documentation concerning the meeting is available to shareholders on the company's website: Precisions regarding the AGM Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight (Paris time), will be able to participate physically in the AGM. Shareholders holding bearer shares ("actions au porteur") will need to obtain a certificate of shareholding ("attestation de participation") from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person. Shareholders must submit written questions no later than the fourth business day prior to the AGM. Questions can be sent by registered mail to the company's registered office or by email to the following address: ag2025@ In order to be considered, questions must be accompanied by an "attestation de participation". About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. View source version on Contacts Adocia Olivier Soula CEOcontactinvestisseurs@ +33 (0)4 72 610 Ulysse Communication Adocia Press & Investor Relations Bruno ArabianNicolas Entzadocia@ + 33 (0)6 87 88 47 26
Business Wire
30-04-2025
- Business
- Business Wire
ADOCIA Announces the Release of its Universal Registration Document for the Year 2024
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today the filing of its 2024 Universal Registration Document with the 'Autorité des marchés financiers' (AMF - the French financial markets regulator) on April 29 th, 2025. An electronic copy of this document is available on the company's website ( as well as on the website of the AMF ( Hard copies are available upon request at the company's headquarters located 115, avenue Lacassagne, 69003 Lyon. The following documents are included in the Universal Registration Document (document d'enregistrement universel): the 2024 annual financial report, which includes the 2024 Management Report, the 2024 Board of Directors' report on corporate governance, the reports from the statutory auditors and information on their fees, the description of the share buy-back program. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext TM Paris (Euronext: ADOC; ISIN: FR0011184241).
